OTLC - Oncotelic Therapeutics posts promising combo cancer therapy data

Oncotelic Therapeutics ([[OTLC]] +2.0%) says that the combination therapy of anti-sense oligonucleotide targeting TGF-?2 ((TASO)) and the IL-2 Proleukin (aldesleukin) has an anti-tumor effect.The combination treatment of trabedersen and low-dose Proleukin decreased cancer cell viability in an in vitro experiment in solid cancer cell lines.Modulation of the dose of Proleukin is expected to help reduce the toxicity of IL-2 and increase the anti-cancer effect in combination with trabedersen, according to a presentation made at the American Association for Cancer Research Annual Meeting.The company also indicated that its lead immuno-oncology drug candidate OT-101 will synergize with IL-2, further demonstrating its utility as adjunct to other immunotherapies.Interleukin-2 (IL-2) immunotherapy is a type of cancer treatment that stimulates the body's immune system to fight cancer, such as melanoma.OT-101, an antisense against an essential protein required for viral replication called TGF-?, had the go-ahead from Peru's health regulator, Instituto Nacional de Salud, for a mid-stage trial testing

For further details see:

Oncotelic Therapeutics posts promising combo cancer therapy data